Neuronetics, Inc. (STIM)
NASDAQ: STIM · IEX Real-Time Price · USD
1.925
+0.025 (1.32%)
At close: Jul 19, 2024, 4:00 PM
1.910
-0.015 (-0.78%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Neuronetics Revenue
Neuronetics had revenue of $73.23M in the twelve months ending March 31, 2024, with 10.01% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $17.42M with 12.08% year-over-year growth. In the year 2023, Neuronetics had annual revenue of $71.35M with 9.42% growth.
Revenue (ttm)
$73.23M
Revenue Growth
+10.01%
P/S Ratio
0.79
Revenue / Employee
$360,714
Employees
203
Market Cap
57.75M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71.35M | 6.14M | 9.42% |
Dec 31, 2022 | 65.21M | 9.89M | 17.89% |
Dec 31, 2021 | 55.31M | 6.07M | 12.32% |
Dec 31, 2020 | 49.24M | -13.41M | -21.41% |
Dec 31, 2019 | 62.66M | 9.88M | 18.72% |
Dec 31, 2018 | 52.78M | 12.34M | 30.53% |
Dec 31, 2017 | 40.43M | 6.21M | 18.13% |
Dec 31, 2016 | 34.23M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rockwell Medical | 86.62M |
LENSAR | 44.50M |
Cytosorbents | 36.69M |
Cryo-Cell International | 31.64M |
CollPlant Biotechnologies | 10.62M |
Adlai Nortye | 5.00M |
Enzo Biochem | 4.72M |
STIM News
- 10 days ago - California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults - GlobeNewsWire
- 11 days ago - BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents - GlobeNewsWire
- 20 days ago - NeuroStar® Launches Better Me Provider Program Nationwide - GlobeNewsWire
- 5 weeks ago - NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting - GlobeNewsWire
- 2 months ago - Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference - GlobeNewsWire
- 2 months ago - Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents - GlobeNewsWire
- 2 months ago - Neuronetics Reports Record First Quarter 2024 Financial and Operating Results - GlobeNewsWire
- 2 months ago - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire